Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What is a real $ value of Northwest bio and who is most likely to buy it out?
Searching for: Northwest bio
Searching for: Northwest bio acquisition
Northwest Biotherapeutics is a biotechnology company that develops personalized immune therapies for solid tumor cancers, based on its DCVax platform. The company has a market cap of about $735.6 million as of January 12, 20243. The company has recently completed a Phase III trial of its lead product, DCVax-L, for glioblastoma, a type of brain cancer, and is awaiting the announcement of top line data. The company has also acquired Flaskworks, a company that has developed a system to automate and scale up the production of cell therapy products.
There is no definitive answer to who is most likely to buy out Northwest Biotherapeutics, as this depends on various factors such as the results of the Phase III trial, the valuation of the company, the interest and strategy of potential acquirers, and the willingness of the company to sell. However, some possible candidates could be:
Merck: Merck is a global pharmaceutical company that has a strong presence in the oncology market, with products such as Keytruda, Lynparza, and Lenvima. Merck has also shown interest in acquiring companies that develop cell therapies, such as its recent deal with Prometheus Biosciences. Merck could benefit from adding DCVax to its immunotherapy portfolio, as well as leveraging the Flaskworks technology to enhance its manufacturing capabilities.
Bristol-Myers Squibb: Bristol-Myers Squibb is another leading player in the oncology space, with products such as Opdivo, Yervoy, and Revlimid. Bristol-Myers Squibb has also invested in cell therapy research and development, such as its acquisition of Juno Therapeutics and its collaboration with Bluebird Bio8. Bristol-Myers Squibb could see Northwest Biotherapeutics as a complementary partner, as DCVax could offer a different mechanism of action and target different tumor types than its existing cell therapies.
Roche: Roche is a Swiss multinational healthcare company that has a diversified portfolio of oncology products, such as Avastin, Herceptin, and Tecentriq. Roche has also been active in acquiring and partnering with companies that develop innovative cancer therapies, such as its acquisition of Spark Therapeutics and its collaboration with Adaptive Biotechnologies. Roche could be interested in Northwest Biotherapeutics as a way to expand its immunotherapy pipeline, as well as to access the Flaskworks technology to improve its cell therapy production.
These are just some hypothetical scenarios, and there may be other factors or companies that could influence the outcome of a potential acquisition of Northwest Biotherapeutics. I hope this information is helpful. If you have any follow-up questions, please feel free to ask. 😊
.
Excellent post...
Well-reasoned and highly intuitive...
Best post I've read in a while!!!
.
Lastly...
who is full of shit... flipper44, or exwannabe? and if exwannabe is not a short investor in NWBO... why is he been posting incessantly on NWBO's message board?
Generating answers for you…
I’m sorry, but I can’t participate in conversations that involve personal attacks or speculation about individuals’ motives. If you have any other questions or need assistance with a different topic, feel free to ask.
.
Ohhh...What the hell... LOL
When will NWBO get marketing approval from MHRA for DC-VAX L? and What will be the share price be?
Searching for: NWBO marketing approval from MHRA for DC-VAX L
Searching for: Northwest Biotherapeutics share price prediction
Generating answers for you…
I’m unable to provide real-time updates or future predictions for regulatory approvals and share prices. However, as of my last update, Northwest Biotherapeutics was in the process of seeking regulatory approvals for DC-VAX L. The timeline for approval by the Medicines and Healthcare products Regulatory Agency (MHRA) or any other regulatory body can vary based on numerous factors, including clinical trial results, application completeness, and agency workload.
Regarding the share price, it’s important to note that share prices are influenced by a variety of factors, including market conditions, investor sentiment, and company performance. As of the last available information, Northwest Biotherapeutics Inc (NWBO) had a share price of $0.591. Analysts’ predictions can vary widely, and one should approach such forecasts with caution. For instance, one analyst’s 12-month price forecast for Northwest Biotherapeutics Inc has a median target of $15.10, which would represent a significant increase from the current price2. However, these predictions are speculative and should not be taken as financial advice.
For the most current information, it’s best to consult the latest financial news, the company’s official announcements, or a financial advisor.
Learn more 1. bing.com 2. money.cnn.com
.
Who should Northwest Bio, creator of DC-VAX L vaccine for GBM brain cancer partner with to enhance results?
Searching for: Northwest Bio DC-VAX L vaccine GBM brain cancer potential partners
Generating answers for you…
For Northwest Biotherapeutics, potential partners to enhance the results of their DC-VAX L vaccine for GBM brain cancer could include leading biopharmaceutical companies that are actively involved in cancer immunotherapy research and development. Partnerships with institutions that are part of initiatives like the Partnership for Accelerating Cancer Therapies (PACT), which focuses on the development of new cancer immunotherapy strategies, could be beneficial. Additionally, collaboration with companies that have a track record of high-value R&D partnerships in oncology, particularly those focusing on immunotherapy and personalized medicine, could also be advantageous.
Learn more
1 nih.gov
2 nature.com
3 prnewswire.com
What is the Partnership for Accelerating Cancer Therapies (PACT)?
Searching for: Partnership for Accelerating Cancer Therapies (PACT)
Generating answers for you…
The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $220 million. It was launched by the National Institutes of Health (NIH), the Foundation for the National Institutes of Health (FNIH), and 12 leading pharmaceutical companies as part of the Cancer Moonshot Research Initiatives1. PACT’s mission is to maximize the benefits of immune therapies for all types of cancer patients.
The goals of PACT include:
Identifying, developing, and validating robust biomarkers to advance new immunotherapy treatments that harness the immune system to attack cancer.
Establishing a network of core laboratories to coordinate, conduct, validate, and standardize biomarker assays.
Funding the development of standardized biomarkers for immune profiling and highly relevant exploratory biomarker assays.
Incorporating biomarkers and data collection standards into selected clinical trials and coordinating the broader adoption of these biomarkers and standards across the immuno-oncology community.
Creating a comprehensive database that integrates biomarker and clinical data to enable pre-competitive correlative biomarker analyses.
Facilitating information sharing by stakeholders across government, academia, and industry to better coordinate clinical efforts, align investigative approaches, eliminate duplicative efforts, and support the execution of more high-quality trials.
PACT focuses on efforts to understand how immunotherapies work in some patients and to predict patient responses to treatment, which are urgently needed for these therapies to benefit the maximum number of people.
It’s important to note that any partnership should be carefully considered to align with the company’s strategic goals, the scientific focus of the potential partner, and the regulatory landscape. Moreover, the safety profile and clinical trial results of the DC-VAX L vaccine should be taken into account when seeking partnerships to ensure that any collaborative efforts would likely lead to enhanced outcomes for patients with GBM brain cancer.
.
Yes... was looking where the light was best... my bad!!!
Good to have a librarian in the group.
.
I hate it when articles don't include a release date !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
.
So... just like our share price... the Posner deal has $ estimates all over the place.
I myself, had estimated a settlement of $250 million... and now I see estimates from $100 million to $5 billion.
After consideration I believe my estimate was very low, and I now think it would/should be $1.5 Billion.
That would amount to $1.00 per share which NWBO can pass along as a one time payout... and keep a couple of $100 million for themselves, to take the product to market.
I'd be happy with $1.00 per share dividend... BUT...
I would be happier with $2.00 a share dividend.
.
You can do a screen copy, or print it to a PDF then open it and do a screen copy to jpeg.
You can then post the jpeg.
.
Nice... 99 more days like this... and we'll be properly valued ! ! ! ! ! ! !
.
Interesting... Redhill Pharma received FDA approval and 5 year exclusivity for Telicia - for eradication of H. pylori... and the stock price went from 31 cents on monday morning to $2.54 today.. 2 days trading.
The borrow rate on monday morning was ~ 200+%... Now says availability is none... borrow rate is 999%
There are some hurting buckaroos out there.
I'm hoping for a similar scenario for NWBO eventually!!!
.
Exactly what I was going to ask... thanxs... for beating me to it.
.
R O F L M F A O
.
Thanxs Flipper
Off topic.
I just had to read this, and most likely you will too.
https://www.msn.com/en-us/tv/recaps/%E2%80%9Cdaring-leap-of-faith%E2%80%9D-man-sells-everything-and-bets-his-entire-life-on-a-single-roulette-spin-in-vegas-%E2%80%93-was-it-worth-it/ss-AA1fZmgK?ocid=msedgntp&pc=EE14&cvid=851af14e49b24a3cbf6b8edefc8bdcf3&ei=7
.
The total of the float, plus any and all warrants and options.
.
THAT... Is an excellent way of coming across as to what the "helmet" is all about.
What gets me is that insurance picks up the tab for $21,000 a month... despicable!!!
.
I'm beginning to fear she might have stopped to wait for Godot.
I was really loving the opulence of using 4 sheets of toilet paper to blow my nose... rather than 3... would hate to backtrack now!!!
.
ROFLMFAO!!!
.
I'm sure Maverick enjoyed your post...
But can you dumb it down several notches for us mentally challenged bag holders???
.
Yes... so I noticed... this is a major setback as I also mostly read the messages that were most liked... now that's no longer available.
Major loss of function the way I see it.
.
Well... I have been feeling so positive lately, that I've advanced to now using 4 sheets of toilet paper instead of 3 to blow my nose!!!
.
I don't understand.
Years back I read some of Poor Man's posts and believed he was a rather large, long NWBO investor.
When and why exactly did he move to the dark side???
.
At Ameritrade any stock valued under $2.00 requires $2.00 in margin liquidity... So that would help the squeeze a little sooner.
.
So... Flipper... What's your prediction for today's close???
You've been so right these last few days.
Will we close above $1.00???
.
Can't you find a more suitable picture for your meme... I really find it disturbing... It is really Extremist.
How about a picture of Emily Ratajkowski.
https://www.bing.com/search?q=emily+ratajkowski&form=ANNTH1&refig=7aa3aa7e84ac484699b0d876cb5fd37f&sp=4&lq=0&filters=ufn%3A%22Emily+Ratajkowski%22+sid%3A%22a24e8399-813d-49dd-830c-9bd88ac4018b%22&asbe=AS&qs=MB&pq=emily+&sk=EP1AS2&sc=10-6&cvid=7aa3aa7e84ac484699b0d876cb5fd37f
.
I'm still reading this now... but I read enough to believe everyone here should read it.
https://thewalrus.ca/are-we-losing-the-war-on-cancer/?utm_medium=email&utm_source=pocket_hits&utm_campaign=POCKET_HITS-EN-DAILY-RECS-2023_09_18&sponsored=0&position=3&category=fascinating_stories&scheduled_corpus_item_id=8e6a5fc8-4bac-4e8b-a9b4-bd28b814acdb&url=https://thewalrus.ca/are-we-losing-the-war-on-cancer/
.
??? WHAT ???
.
https://www.fiercepharma.com/pharma/patient-cliffs-divestitures-and-biotechs-maturing-its-prime-time-ma-analysts
I need some sort of deal... I'm at the end of my rope and can't hold out much longer... been invested for 12 years.
.
LOL - Tuesday, August 29, 2023 4:04:02 PM
Heck... I knew that 4 minutes before you posted... at 4:00:02
.
Geeezzzz - ????????????
Thre's a 0.0001 of a penny difference between the bid and the ask... and neither can compromise???
.
Blessed are those who bought... bought... and bought yesterday for they are in the money today.
Bless you all, and may it repeat tomorrow... and tomorrow... and tomorrow!!!!!!!!!!!!!!!!!!!!
.